Castle Biosciences Announces the Appointment of Frank Stokes as Chief Financial Officer

FRIENDSWOOD, Texas--(BUSINESS WIRE)-- Castle Biosciences, a provider of molecular diagnostics to improve cancer treatment decisions, today announced the appointment of Frank Stokes as Chief Financial Officer (CFO). Mr. Stokes has extensive experience leading capital formation for high-growth companies, most recently as CFO of Hammock Pharmaceuticals and previously as a Senior Investment Banker at Leerink Partners. He joined Castle Biosciences effective December 4, 2017.

“Frank brings financial accumen, expertise in capital markets, success with mergers and acquisitions, and a deep knowledge of the diagnostics industry—all of which will help our team continue our mission to improve patient care decisions and deliver shareholder value,” commented Derek Maetzold, President and CEO of Castle Biosciences. “With two commercial products, a robust pipeline, and a strong base of clinical data, Castle Biosciences is well-positioned to leverage his strengths as we target our combined U.S. market opportunity of nearly $2 billion and continue to deliver strong growth in revenue and test volumes.”

Mr. Stokes joins Castle Biosciences with more than 20 years of experience in finance. As Chief Financial Officer of Hammock Pharmaceuticals, he assisted in the initial capitalization of the company, as well as the acquisition of Hammock’s foundational drug delivery technology. Prior to Hammock, Mr. Stokes served as a Senior Investment Banker at Leerink Partners, Robert W. Baird, and Wachovia Securities (now Wells Fargo Securities). Mr. Stokes received a B.S. in business administration followed by MBA and J.D. degrees from the University of North Carolina at Chapel Hill.

About Castle Biosciences

Castle Biosciences is a molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about their treatment and follow up care based on the individual molecular signature of their tumor. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx^®-Melanoma; www.SkinMelanoma.com) and uveal melanoma (DecisionDx^®-UM, DecisionDx^®-PRAME; www.MyUvealMelanoma.com), with development programs in other underserved cancers. Castle Biosciences is based in Friendswood, TX (Houston), and has laboratory operations in Phoenix, AZ. More information can be found at www.CastleBiosciences.com.

DecisionDx-Melanoma, DecisionDx-UM and DecisionDx-PRAME are the trademarks of Castle Biosciences, Inc. Any other trademarks are the property of their respective owners.

View source version on businesswire.com: http://www.businesswire.com/news/home/20171207005285/en/